Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
Departments of aInternal Medicine bCardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Anurag
A
Mehta
Arjun
A
Gupta
Franck
F
Hannallah
Thomas
T
Koshy
Sharon
S
Reimold
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000074324:Ipilimumab / Q000008:administration & dosage / Q000009:adverse effects; D008545:Melanoma / Q000188:drug therapy*; D009205:Myocarditis / Q000139:chemically induced*; D000077594:Nivolumab
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D000077594:Nivolumab